Timo Hnninen appointed CEO of Injeq Oy


Injeq Oy
Press release
February 10, 2022 at 12:00 p.m. (EET)

Timo HanninenPh.D., MBA, has been named CEO of Injeq Oy. Hänninen will take office at 14.2.2022. Hänninen previously served as CEO of RUAG Space Finland Oy AB.

Timo Hanninen is a professional with a long experience in the management of technological organizations. He has extensive experience in international business development and strategy. During his career, Hänninen has worked in the fields of medical technology, cybersecurity and space technology, as well as in management positions at Nokia Company For almost 20 years.

Hänninen’s training is also diverse. He did his master’s thesis on medical technology, his MBA work focused on ethical management at Nokia, and his thesis focused on investor reactions to corporate merger and acquisition announcements.

Hänninen is interested in the high technology of Injeq and the global market. It is also important to him that Injeq is a Finnish company whose product can improve people’s lives. “Injeq is a truly international company that creates something new. I see the purpose of the job as an important motivating factor,” says Hänninen.

Hänninen describes himself as a pragmatic leader who leads on the basis of facts. “I am open, listen and respect everyone in the organization. I want to challenge the organization, and as a team player, I believe in innovation by individuals and working together” , believes Hänninen.

“I am very pleased that a professional management CEO with extensive experience and strong business vision has been appointed to Injeq. We are an international growth medical high-tech company that has need expertise like Hänninen”, said the chairman of the board of directors of Injeq and acting. CEO Tommi Rasila.

Hänninen has solid experience in introducing new technologies to the markets. At Nokia, he was selling cellular networks in areas where even wired phone networks didn’t work perfectly.

More information

Injeq Oy

Tommi RasilaChairman of the Board, Interim CEO
Phone. +358 40 750 8158
[email protected]

Timo HanninenCEO since 14.2.2022
Phone. +358 50 518 1830
[email protected]

Injeq in a nutshell

Injeq Oy is a growing Finnish company in the field of innovative medical technologies, whose mission is to produce technically intelligent solutions for injections of medically demanding patients. Developed at the request of doctors, the IQ-Tip® smart needle makes it easier for doctors to improve patient safety and treatment efficiency.

The IQ-Tip® smart needle is a modern way to safely perform demanding injections for patients. The first step is the lumbar puncture, a clinical procedure in which cerebrospinal fluid is removed or medication is administered into the spinal cavity. The clinical performance and safety of the product in lumbar punctures has been evaluated in three clinical trials at Finnish university hospitals. The smart needle is suitable for lumbar puncture from newborns to the elderly, with one of the main uses being the treatment of children with leukemia.

Founded in 2010, Injeq operates in Tampere and currently employs 16 people. Injeq is backed by an experienced team of medical experts and extensive scientific research. IQ-Tip® is a registered trademark of Injeq.




(c) Decision 2022. All rights reserved., sources Press Releases – English


Comments are closed.